Skip to main content
OpenTrials
Completed

NCT Number: NCT01982006

Economic Evaluation of Femtosecond Laser Assisted Cataract Surgery

Cataract is the leading cause of blindness worldwide and cataract surgery is the most frequent surgery performed in France. A new technology, the femtosecond laser-assisted cataract surgery, has to be compared with phacoemulsification alone, the conventional cataract surgery, to determine the economic impact of femtosecond laser-assisted process for the French healthcare insurance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CHU de Bordeaux, Bordeaux, France

Loading trial locations.

About this study

An estimated 700,000 cataract procedures are performed every year in France, with this amount of surgeries predicted to climb as the population there, as well as around the world, ages. Currently, phacoemulsification alone is the conventional cataract surgery. The femtosecond laser-assisted cataract surgery has to be compared with the standard process to provide information on how it could benefit the patient population treated every year for cataract surgery. This economic study has received a grant from the French Ministry of Health to evaluate the economic impact of femtosecond laser-assisted process for the French healthcare system. For this goal, this prospective, randomized, parallel, multicenter and simple blind study will determine the incremental cost/effectiveness ratio for femtosecond laser-assisted process versus phacoemulsification surgery. Visual acuity results and intraoperative or postoperative complication rate will be compared between both groups. The learning curve of the femtosecond laser assisted cataract surgery will be also evaluated for each surgeon involved in the study.

Ethic and regulatory autority authorisations were obtained at 19/Dec/2012 and 15/Feb/2013, respectively. Date of first inclusion: 9/Oct/2013. Date of first NCT release: 13/Nov/2013. 30 patients were included between this period. French regulatory process dos not require NCT registration before first inclusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cataract with impaired visual acuity (> or equal +0.3 LogMAR) or with cataract-related visual symptoms (Halos, Monocular diplopia, glare)
  • French healthcare insurance beneficiary

Exclusion criteria

  • Pupil size lower than 6mm
  • Iris constriction
  • Iris synechiae
  • Preoperative zonular instability or crystalline lens subluxation
  • Obstructive Corneal scars
  • Obstructive pterygion
  • Axial length <20.5 mm
  • Corneal astigmatism >1.5 diopters
  • Fuchs corneal dystrophy
  • History of Central retinal vein or artery occlusion
  • History of uveitis
  • History of optic nerve head neuropathy except glaucoma
  • Progressive glaucoma
  • Nystagmus
  • Uncontrolled diabetes mellitus
  • General history of dementia or psychotic disorders
  • Pregnancy, breast feeding
  • General medications: Alpha-blockers, Carbonic anhydrase inhibitors

Treatment and study plan

Cataract surgery with Phacoemulsification

Procedure

Each patients randomized in the phaco arm will undergo a conventional cataract surgery.

Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.

Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center.

Femtosecond laser-assisted cataract surgery

Device

Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.

Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.

Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm

Primary outcomes

  1. Incremental Cost/effectiveness ratio defined as cost per incremental therapeutic success.

    Time frame: 3 months after inclusion

    Therapeutic success will be defined by the association of the following criterion:

    • No severe intraoperative or postoperative complications,
    • Best Corrected Visual Acuity of 0 LogMAR,
    • A refractive error inferior or equal to 0.75 diopter,
    • Corneal surgically-induced astigmatism inferior or equal to 0.5 diopter and a postoperative change of astigmatism axis inferior or equal to 20°.

Secondary outcomes

  1. Quality of life

    Time frame: Before surgery (From day -8 to day -1) and months 1, 3 and 12 after surgery

    Quality of life evaluation using Visual Function 14 questionnaire

  2. Learning curve of the femtosecond laser-assisted cataract surgery

    Time frame: End of research (Month 12)

  3. Overall costs of cataract surgery in both arms from the hospital perspective

    Time frame: End of research (Month 12)

  4. Incremental cost - Utility ratio defined as incremental Cost/QALY (Quality Adjusted Life Year) for healthcare insurance in both arms

    Time frame: 12 months after inclusion

  5. No severe intraoperative or postoperative complications

    Time frame: 3 months after inclusion

  6. Best Corrected Visual Acuity of 0 LogMAR

    Time frame: 3 months after inclusion

  7. Refractive error inferior or equal to 0.75 diopter

    Time frame: 3 months after inclusion

  8. Corneal surgically-induced astigmatism inferior or equal to 0.5 diopter and a postoperative change of astigmatism axis inferior or equal to 20°

    Time frame: 3 months after inclusion

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Impact Médico-Economique de la Chirurgie de la cATaracte au Laser Femtoseconde

Acronym: FEMCAT

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Nov 13, 2013
Registry last updated
Oct 4, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.